Two new genetic testing services available from this reference lab can help to identify problems with patient response to drug therapies.
The Gleevec (Imatinib) resistance mutation analysis identifies the T3151 mutation commonly associated with resistance in chronic myelogenous leukemia (CML) patients.
Gleevec can be highly effective in treating chronic myelogenous leukemia (CML). However, resistance can occur, and identifying resistance early may be helpful in determining if a new course of therapy is warranted. The Gleevec resistance assay offered by this reference lab complements it’s comprehensive line of testing for CML disease management.
This company also now offers the TPMT Mutation Analysis, a genetic test for identifying mutations associated with poor thiopurine drug metabolism.
Thiopurines (e.g., 6MP, Azathioprine) are used in treating a number of disorders including leukemias, Crohn’s disease and rheumatoid arthritis. Identifying individuals who are poor metabolizers of the drugs is important in helping to prevent hepatic toxicity and other adverse effects.
This assay complements the lab’s comprehensive line of testing in gastroenterology, rheumatology and oncology.
Specialty Laboratories
www.CLPmag.com
Keywords: reference test
